Tudca (Tauroursodeoxycholic Acid) for Neuroprotection

Research suggests that TUDCA holds meaningful neuroprotective potential across a broad range of conditions, with the evidence base drawing from multiple 2020–2026 reviews, several preclinical animal and cell-based studies, and early-phase human clinical trials. Studies indicate that TUDCA works through several overlapping biological mechanisms — including reducing programmed cell death, lowering oxidative stress, protecting mitochondria, easing endoplasmic reticulum stress, stabilizing misfolded proteins, and dampening neuroinflammation — and these effects have been observed in experimental models of Alzheimer's, Parkinson's, Huntington's, ALS, spinocerebellar ataxia, traumatic brain injury, retinal degeneration, and perioperative cognitive decline. The most clinically advanced evidence comes from ALS, where phase II trials found TUDCA to be safe and potentially disease-modifying, and a large phase III trial is currently underway with results not yet published; an interesting complication is that one case-control study found ALS patients already had modestly elevated blood levels of TUDCA compared to healthy controls, raising questions about how supplementation interacts with this baseline. While the overall direction of the research is consistently supportive, the evidence remains largely preclinical, and researchers themselves note that substantial gaps must be addressed before TUDCA could be broadly recommended as a therapeutic agent in humans.